Background and Aims: A subset of patients who undergo ileal pouch-anal anastomosis [IPAA] for ulcerative colitis [UC] will later be diagnosed with denovo Crohn's disease [CD]. These patients have a higher risk of pouch failure. In this study we evaluated inflammatory bowel disease [IBD] serology in patients with denovo CD and examined the success of anti-tumour necrosis factor-alpha [anti-TNFα] therapy in preventing ileostomy in denovo CD patients who failed anti-TNFα therapy before IPAA. Methods: A prospectively maintained database of patients undergoing IPAA was reviewed to identify patients who developed denovo CD [defined as small bowel inflammation above the pouch inlet or pouch fistula/perianal disease appearing more than 3 months after stoma closure]. Clinical characteristics and IBD serology were analysed. Treatment failure was defined as pouch failure requiring ileostomy or pouchectomy. Results: Of 350 patients included in the study, 92 [26%] patients developed denovo CD. Significantly more denovo CD patients had anti-I2 positivity postoperatively versus preoperatively [p = 0.007]. Anti-TNFα therapy successfully treated denovo CD in 28 out of 38 [74%] patients. Out of 17 patients with denovo CD who had failed to respond to anti-TNFα agents before surgery and were treated with anti-TNFα therapy after surgery, 12 [71%] patients responded to treatment. Conclusions: I2 serology may possibly help identify patients who have developed or are at risk for developing denovo CD. Anti-TNFα therapy for denovo CD after IPAA can help prevent permanent ileostomy in almost 75% of cases, even in patients who previously failed anti-TNFα treatment before surgery.
Introduction
Total proctocolectomy with ileal pouch-anal anastomosis [IPAA] is the standard surgery performed for patients with medically refractory ulcerative colitis [UC] . One of the leading causes of pouch failure in patients after IPAA is the development of denovo Crohn's disease [CD] . 1, [3] [4] Up to 15% of patients who undergo IPAA for an original diagnosis of UC will eventually be diagnosed with CD. 2, [5] [6] [7] Given that patients with CD are at a higher risk for pouch failure, the ability to decide which patients have an increased risk of developing denovo CD would be useful for patient management. Furthermore, patients who develop denovo CD often have similar symptoms to patients with other diseases such as pouchitis, cuffitis, and irritable pouch syndrome, which can make the diagnosis challenging. 8 The ability to easily distinguish denovo CD from these other entities by noninvasive testing such as serology would allow these patients to begin appropriate treatment in a more expedited manner.
In an effort to better risk-stratify patients undergoing IPAA, studies have identified risk factors for denovo CD including smoking, family history of CD, female gender, younger age, mouth ulceration, and the presence of preoperative anal fissure or fistula. [9] [10] [11] [12] [13] However, these risk factors are nonspecific and have not been consistent across all studies. Several antibodies have previously been identified which may be helpful in distinguishing CD from UC and other gastrointestinal disorders. Antibodies to microbial antigens including anti-Saccharomyces cerevisiae antibodies [ASCA], antiflagellin [anti-CBir1], anti-outer membrane porin C [anti-OmpC], and anti-Pseudomonas fluorescens-associated sequence I2 [anti-I2] tend to be higher in patients with CD, whereas anti-nuclear cytoplasmic antibodies [ANCA] tend to be higher in patients with UC. 14 In IPAA patients, denovo CD has been associated with positivity of ASCA IgA and IgG, anti-CBir1, and anti-glycoprotein 2 [GP2]. [11] [12] [15] [16] [17] However, results have not been consistent across all studies. Notably, all of these studies have measured serology either before or after surgery, but have not looked for changes in serology over time.
Beyond being able to predict denovo CD, another challenge in patients who develop denovo CD is determining management, as relatively few data are available in this regard. Small studies have suggested that both infliximab and adalimumab may have shortterm and/or long-term efficacy in the treatment of denovo CD after IPAA. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] However, these studies evaluated response to only one anti-TNFα agent or did not specifically evaluate whether patients had already been treated with anti-TNFα therapy before IPAA. This is an important distinction, because approximately one-third of patients with UC are treated with anti-TNFα therapy before surgery. 28 Given that many patients have failed anti-TNFα therapy before surgery, it is important to determine if this type of therapy after surgery is effective for these patients.
In this study, we evaluated whether IBD serology changed over time with disease diagnosis and examined whether there were differences in serology between patients who developed denovo CD versus patients who did not develop pouch inflammation. We also investigated whether patients who failed anti-TNFα therapy before IPAA responded to anti-TNFα agents after surgery.
Materials and Methods

Study population
A prospectively maintained database including patients with UC or IBD-unclassified [IBDU] who underwent IPAA at Cedars-Sinai Medical Center for medically refractory disease, cancer, or dysplasia from 1993 to 2014 was reviewed. Complete mucosectomy was performed in all patients by one surgeon and all patients had a temporary diverting ileostomy constructed at the time of pouch creation. Patients were seen in follow-up every 3 months for 1 year after stoma closure and then yearly thereafter, with pouchoscopy performed at all scheduled follow-up examinations by a colorectal surgeon. Patients with acute issues had more frequent visits, and many patients were followed concomitantly by a gastroenterologist in between colorectal surgery visits. All research-related activities were approved by the Cedars Sinai Medical Center Institutional Review Board [IRB# 37735].
Assessment of clinical characteristics
Detailed clinical information for each of the study patients was obtained via chart review and patient interview during routine office visits. Clinical information included age at disease diagnosis, age at colectomy, disease extent, disease duration, family history of IBD, history of smoking, and presence of extraintestinal manifestations of IBD. Ulcerative colitis was diagnosed preoperatively based on clinical, endoscopic, pathological, and imaging criteria. UC patients had continuous inflammation extending proximally from the dentate line, with no perianal disease and no evidence of strictures or small bowel disease on radiological evaluation. Patients were classified preoperatively as having IBDU when they had atypical features suggestive but not diagnostic of CD, such as discontinuous inflammation on endoscopy, presence of crypt-associated granulomas, distant history of superficial anal fistula or ulcer, or limited small bowel inflammation greater than 3 cm proximal to the ileocecal valve on endoscopy. Disease extent was classified as left-sided colitis, pancolitis, or proctitis based on preoperative endoscopic findings. Backwash ileitis was defined as macroscopic or histological inflammation restricted to the distal 3 cm of the terminal ileum and not thought to be CD. Disease duration was defined as the time in months from date of disease diagnosis to date of colectomy. 
Serological analysis
Serum drawn within 30 days of colectomy was considered to be serum drawn at colectomy. Serum drawn post-colectomy was included if the serum was drawn at least 180 days after colectomy. If multiple sera were available, the serum drawn furthest from date of colectomy was chosen for analysis. IBD serologies [ASCA IgG and IgA, ANCA, anti-CBir1, anti-OmpC, anti-I2] were measured by enzyme-linked immunosorbent assay [ELISA] as described previously 30 and antibody levels were determined. Results were expressed as ELISA units [EU/ml] relative to Cedars-Sinai Medical Center laboratory or a Prometheus laboratory standard derived from a pool of patient sera with well-characterized disease found to have reactivity to these antigens. Antibody positivity was defined as being greater than cut-off value 2 standard deviations above mean control titre s for each assay. All assays were performed blindly without any knowledge of patient characteristics.
Diagnosis of denovo CD
Patients were diagnosed with denovo CD when there was either afferent limb inflammation at any time after IPAA or when a pouch or perianal fistula occurred at least 3 months after stoma closure. Time to diagnosis of denovo CD was defined as time in months from ileostomy closure. Patients developing pouchitis [acute or chronic] or using non-steroidal anti-inflammatory medications were excluded from analysis. Pouchitis was confirmed in all cases by endoscopy with afferent ileal limb intubation. Endoscopic findings included diffuse mucosal inflammation, typically involving the entire pouch, characterized by exudate, ulceration, erythema, and sparing of the afferent ileal segment. Acute pouchitis was defined as flares occurring at least 4 months apart during which the patient returned to his or her usual bowel pattern with antibiotic use. Chronic pouchitis required continuous antibiotic use, or more frequent antibiotic use than 4 months apart, or was not responsive to antibiotic therapy. Pouchoscopy with biopsies was performed in all chronic pouchitis patients to rule out granulomatous inflammation or cytomegalovirus inclusion bodies. Stool studies were performed to rule out infection.
Assessment of treatment response
Treatment failure preoperatively was defined as the need for IPAA due to disease activity. Patients who had IPAA for cancer or dysplasia were excluded from analysis of preoperative treatment response. Treatment failure postoperatively was defined as pouch failure requiring ileostomy. Patients were considered primary anti-TNFα nonresponders if there was no improvement in symptoms with treatment. Patients were considered secondary anti-TNFα nonresponders if initial improvement in symptoms was followed by eventual worsening of disease, requiring surgery. Follow-up time was defined as the time in months from stoma closure to last office visit or patient contact during which information was obtained regarding the patient's current clinical status.
Statistical analysis
All data were entered into a standardized computer database [Microsoft Excel, Seattle, WA]. The Fisher exact test was used to compare categorical variables. Student's t-test was used to compare means for continuous variables. All hypothesis testing was two-sided with p-value less than 0.05 considered to be statistically significant.
Results
Patient demographics and characteristics
Out of 562 patients in the database, 67 patients were excluded from analysis because stoma closure was never performed [ [n = 5, 12%] versus patients not treated with those agents [n = 16, 32%; p = 0.04]. Age at colectomy, age of disease onset, sex, disease extent, disease duration, and family history of IBD were not significantly different between patients who were treated with anti-TNFα agents before surgery versus those who were not.
IBD serology
IBD serology at the time of colectomy was compared between patients who did not develop pouch inflammation and patients who developed denovo CD [ Table 2 ]. There were no significant differences in positivity or mean antibody level of IBD serologies between patient groups who did or did not develop denovo CD. IBD serology was compared in denovo CD patients both postoperatively and at the time of colectomy, to look for changes in serology over time [ Table 3 
Treatment outcomes in denovo CD
Discussion
Denovo CD is among the leading causes of pouch failure after IPAA, and therefore predicting which patients are at risk for developing the disease, identifying the disease, and determining which treatments are effective, are of utmost importance. In this study we found that in the denovo CD group only, significantly more patients developed anti-I2 positivity after IPAA [closer to the time of CD diagnosis] versus before IPAA, suggesting that I2-antibody may be an important marker of the transition to CD in these patients. We also found that anti-TNFα therapy may be an effective treatment in patients with denovo CD after IPAA despite previous failure with this therapy. CD, Crohn's disease; pANCA, anti-nuclear cytoplasmic antibodies; ASCA, anti-Saccharomyces cerevisiae antibodies; anti-OmpC, anti-outer membrane porin C; anti-I2, anti-Pseudomonas fluorescens-associated sequence I2; antiCBir1, anti-flagellin. The fact that I2 serology changed over time in our study has several important implications. First, it may help us to further characterise the pathogenesis of denovo CD. There are three possibilities for how patients may develop CD after IPAA: the diagnosis was missed before surgery; new disease developed after IPAA; or the previous disease transformed into CD. Given that patients who developed CD did not have distinct serology at the time of colectomy, and that serology changed over time in patients who developed CD, this would suggest that the CD was not a missed diagnosis but rather a new disease or a disease transformation. IBD pathogenesis is thought to involve the dysregulation of the immune system's response to bacteria in the gut. 29 The development of a new antibody to the Pseudomonas fluoroscens bacterial antigen may suggest that the symptoms of CD in these patients are in part related to a new loss of tolerance to this gut bacteria. Beyond a further understanding of pathogenesis, I2 serology may prove to be helpful in early detection of denovo CD of the pouch, which could lead to more timely initiation of appropriate management. Although serology is unlikely to be sufficient to make a diagnosis of CD, it could prompt further investigation to rule out the development of CD in a patient presenting Anti-TNF Naive n=51 with symptoms. It is currently unclear at exactly which point in time these patients developed anti-I2 positivity in relation to their symptoms and this would need to be evaluated in further studies. It is notable that denovo CD patients had a higher prevalence of ASCA IgG positivity over time. Although this difference did not reach statistical significance, this should be evaluated in larger studies in the future.
Beyond disease diagnosis, our study also provided useful information in terms of disease management. Currently there is no clear consensus on appropriate management of CD after IPAA. Several small studies have evaluated the efficacy of adalimumab and infliximab therapy for the treatment of this disease and determined that these may be effective treatments. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The largest of these studies was performed by Li et al., who evaluated the effectiveness of adalimumab therapy in 48 patients who developed CD after IPAA. This study found that at short-term follow up [median 8 weeks], 70% of patients had a clinical response. At a longer follow-up of median 25.1 months, 54% had a sustained remission. Nine patients were treated with infliximab before surgery and six of these patients ended up responding to adalimumab therapy. 21 Although only 38 patients with denovo CD in our study were treated with postoperative anti-TNFα therapy, this is one of the largest studies to date to evaluate treatment outcomes in this selected group of patients. Almost 75% of our patients treated with anti-TNFα therapy after surgery had successful treatment without requiring pouch removal or diverting ileostomy. Even our 17 patients who had failed anti-TNFα therapy before surgery had a similar response rate. Interestingly, five of these patients were primary nonresponders to anti-TNFα therapy before IPAA, suggesting that anti-TNFα therapy should be considered even in patients previously highly resistant to therapy. Four patients were treated with the same anti-TNFα agent that they had failed before surgery and did not have pouch failure. This is encouraging data for denovo CD patients and, given that treatment response differs after surgery, this information provides further support for the idea that denovo CD may be a distinct disease from the preoperative diagnosis. Of note, patients who did not receive anti-TNFα therapy had even better outcomes than patients treated with this therapy, but this is likely due to the fact that these patients had less severe disease, as we found a lower prevalence of fistulising disease in these patients.
Despite the knowledge gained from our study, there are also limitations. The most evident limitation is the small amount of subjects included in the study. The number of patients who undergo IPAA surgery and subsequently develop denovo CD is relatively small and it is therefore difficult to find statistically significant differences between this population and others. Only a small number of patients in our study had available postoperative serology to analyse, and this limited the study even further. More of the CD patients in our study were ASCA IgA positive and anti-Cbir1 positive versus the patients without pouch inflammation, but this difference did not reach significance. Some of these differences may therefore be due to a type II error, given our small population of patients with available serology. The proportion of patients in our study who were treated with anti-TNFα therapy both preoperatively and postoperatively was particularly small. In the future, as the amount of patients treated with anti-TNFα therapy preoperatively increases according to the increased use of anti-TNFs over recent years, it will be interesting to re-evaluate outcomes with a larger population of patients. Furthermore, a prospective study would provide more conclusive information regarding whether serology may actually predict the development of denovo CD. Another limitation is the lack of information available regarding clinical symptoms and quality of life with the use of anti-TNFα therapy. Although pouch failure is an important endpoint that likely affects both clinical symptoms and quality of life, other clinical and endoscopic endpoints, if available, could potentially provide further information.
Of note, the percentage of patients who developed denovo CD in our study was higher than previously reported in the literature. This is unlikely to be due to the inclusion of IBDU patients, since excluding the IBDU patients still results in a high prevalence of 23% of denovo CD. The high prevalence may in part be due to the fact that the acute pouchitis and chronic pouchitis patients were excluded from the study, as the percentage of denovo CD drops from 26% to 19% if the acute and chronic pouchitis patients are included. Patients with acute and chronic pouchitis were excluded from the study group because pouchitis may represent a spectrum of disease that overlaps with denovo CD. Acute pouchitis which is initially antibiotic responsive can eventually progress into chronic antibiotic-resistant pouchitis. In one study, as many as 20% of cases of acute pouchitis evolved into chronic pouchitis. 31 Furthermore, gene expression analysis studies have shown that there is a 95% overlap in gene expression alterations between patients with CD of the pouch and chronic pouchitis, again suggesting that these disease entities may in fact represent varying phenotypes on a disease spectrum. 32 Our exclusion of these patients in order to maintain a true control group for comparison therefore seems appropriate.
In summary, our study showed that anti-I2 serology differed at the time of colectomy versus postoperatively in patients with denovo CD. Given that the diagnosis of the disease can be challenging, anti-I2 may prove to be helpful in detecting denovo CD early in these patients. Although denovo CD is associated with a higher rate of pouch failure, we found that anti-TNFα therapy can help prevent pouch failure in the majority of patients, even in those who had failed anti-TNFα therapy before surgery.
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Treatment Success
Denovo CD Patients n=17 n=5 71% n=6 75% n=1 50%
Primary Nonresponder n=7
Reasons for initial therapy discontinuation Secondary Nonresponder n=8
Adverse reaction to Anti-TNF n=2 Figure 2 . Denovo CD patients treated with anti-TNFs before and after surgery.
